Realtime | Geld | Brief | Zeit |
---|---|---|---|
3,440 | 3,580 | 28.06. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
25.04. | Zydus Lifesciences Limited Signs Purchase Agreement with PAI Partners and Other Shareholders to Acquire a Majority Stake in Amplitude Surgical SA | 348 | Business Wire | Regulatory News:
Amplitude Surgical SA (Paris:AMPLI):
Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited ("Zydus") and Amplitude Surgical SA (Paris:AMPLI) ("Amplitude")... ► Artikel lesen | |
17.04. | Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates | 261 | Business Wire | Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over... ► Artikel lesen | |
17.04. | Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares | 249 | PR Newswire | AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of... ► Artikel lesen | |
17.04. | Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares | 226 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited... ► Artikel lesen | |
26.03. | Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA | 326 | Business Wire | Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position... ► Artikel lesen | |
12.03. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 191 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
AMPLITUDE SURGICAL Aktie jetzt für 0€ handeln | |||||
11.03. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 213 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
11.03. | Zydus Life inks pact to acquire majority stake in Amplitude Surgical | 2 | capitalmarket.com | ||
11.03. | Zydus Enters Exclusive Negotiations with PAI Partners and Other Shareholders to Acquire a Majority stake in Amplitude Surgical, France | 340 | Business Wire | Completion of the transaction to be followed by mandatory simplified tender offer
Zydus has entered into exclusive negotiations to acquire a controlling shareholding in Amplitude Surgical,... ► Artikel lesen | |
20.02. | Amplitude Surgical - 1st Half-year 2024-25: Consolidated Sales of €51.5m, +6.3% at Constant Exchange Rates | 302 | Business Wire | Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
Good sales growth in France at +4.6%
Strong growth in international business thanks to subsidiaries, with... ► Artikel lesen | |
21.11.24 | Amplitude Surgical - First Quarter 2024-25: Consolidated Sales of €21.8m, +7.5% at Constant Exchange Rates | 574 | Business Wire | VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics... ► Artikel lesen | |
20.11.24 | Amplitude Surgical Announces Its 2024-25 Financial Calendar | 117 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its financial agenda... ► Artikel lesen | |
23.10.24 | Amplitude Surgical - Fiscal Year 2023-24: 106.0 M€ Sales and €27.1m EBITDA | 486 | Business Wire | Consolidated sales of €106.0 million, up 6.3% at constant exchange rates
EBITDA up to €27.1m (+3.7%), EBITDA rate at 25.6%.
Current operating income of €12.7 million
Cash... ► Artikel lesen | |
25.07.24 | Amplitude Surgical - Consolidated Annual Sales of €106.0m, up +6.3% at Constant Exchange Rates | 281 | Business Wire | Growth of 7.0% at constant exchange rates in the fourth quarter of FY 2023-2024 and 6.3% for the full year
5.0% sales growth in France
Good momentum outside France, with sales up... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BICO GROUP | 3,210 | -0,25 % | Bico Group Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
PING AN HEALTHCARE | 0,946 | +1,42 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
ORGANON | 8,522 | +1,24 % | Dividendenbekanntmachungen (12.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADT INC US00090Q1031 0,055 USD 0,0478 EUR ALAMOS GOLD INC CA0115321089 0,0342 CAD 0,0218 EUR ALIBABA GROUP HOLDING LTD ADR US01609W1027 1... ► Artikel lesen | |
EMEIS | 10,650 | +0,28 % | emeis 2025 Annual General Meeting | Summary of Voting Results
Regulatory News:
emeis (Paris:EMEIS):
Guillaume Pepy, Chairman of the Board of Directors:"Today, we are particularly proud to announce, together with the Board... ► Artikel lesen | |
CYTOSORBENTS | 1,028 | -0,19 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR | PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
CLARIANE | 5,115 | +1,09 % | Clariane has successfully completed a bond issue of 400 million euros | ||
ARJO | 3,052 | -0,97 % | Arjo announces date for 2025 Q2 and conference call | ||
M3 INC | 11,800 | +0,85 % | M3-Aktie kann sich nicht behaupten: Kurs fällt um 5,26 Prozent (12,60 €) | Die Aktie von M3 zählt am Montag zu den großen Verlierern an der Börse. Das Papier verliert deutlich an Wert. Zu den auffälligsten Werten an der Börse gehört heute die M3-Aktie. Das Papier verzeichnet... ► Artikel lesen | |
DYNAVOX GROUP | 10,090 | 0,00 % | TOBII AB: Tobii extends contract with Dynavox Group and agrees on volume deal of eye tracking components | Tobii AB and Dynavox Group AB today announced the strengthening of their partnership with an extension of the existing supply contract, along with a significant volume deal for eye tracking components... ► Artikel lesen | |
NYXOAH | 6,270 | -2,18 % | Nyxoah: Information on the total number of voting rights and shares | ||
INTERPACE BIOSCIENCES | 0,720 | 0,00 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"... ► Artikel lesen | |
CHINA MEDICAL SYSTEM | 1,280 | 0,00 % | China Medical System Holdings Ltd. Holdings Limited: Proposed Secondary Listing on the Singapore Exchange | SHENZHEN, CHINA, June 25, 2025 (GLOBE NEWSWIRE) -- The board of directors of China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group") announces the proposed... ► Artikel lesen | |
NANOSONICS | 2,240 | 0,00 % | NANOSONICS LIMITED: Ceasing to be a substantial holder | ||
VIVANI MEDICAL | 1,030 | +0,98 % | Vivani Medical-Aktionäre wählen Vorstand und genehmigen wichtige Anträge bei Jahresversammlung | ||
NIAGEN BIOSCIENCE | 12,100 | +8,04 % | Niagen Bioscience, Inc. - 8-K, Current Report |